ParfumGigi@aol.com
ParfumGigi@aol.com29 juin, 2006 17:11
Dean Baker Prescription Drug Scams
http://www.truthout.org/docs_2006/062906J.shtml
"The system of patent-financed prescription drug research has supported the growth of an incredibly corrupt and inefficient pharmaceutical industry," writes Dean Baker. "The patent system is bad for the public's health and bad for the economy and bad for jobs. If the industry didn't own the politicians, someone would be talking about changing it."
Marketplace Health Coverage
The Food and Drug Administration is said to be close to lifting the 14-year ban on silicone breast implants. Cosmetic surgeons — and some of their patients — can hardly wait. Helen Palmer reports. (June 29, 2006)
Tenet's $700 million settlement
Hospital chain Tenet was accused of scamming the Medicare system and consequently the nation's older folks. Today, the company agreed to pay more than $700 million to settle the allegations. Amy Scott reports. (June 29, 2006)
Boston Scientific, the largest maker of heart regulation devices, has issued a recall for thousands of its products. Helen Palmer has more. (June 27, 2006)
News yesterday that a scientific study found Vioxx raised risk of heart attacks after as little as four months of use could hurt Merck's legal strategy against many Vioxx lawsuits. Stacey Vanek-Smith explains. (June 27, 2006)
A consumer advocacy group is calling on federal regulators to crack down on businesses that claim laser acupuncture can help smokers kick the habit. Alex Cohen reports. (June 26, 2006)
No surprise that the cost of brand-name prescription drugs is on the rise, but a new study reveals the cost has skyrocketed this year — three times faster than the rate of inflation. Stacey Vanek-Smith reports. (June 23, 2006)
Get ready for statin price wars
If there was ever a good time to have high cholesterol, this might be it. The patent on the cholesterol-lowering statin drug, Zocor, expires today. So, generics will soon hit the market, bringing prices down. Helen Palmer reports. (June 23, 2006)
Merck to compete with Zocor generic
Today Merck's blockbuster cholesterol-lowering drug Zocor loses its patent. Usually when a brand drug goes generic, the price drops sharply. But Merck's not giving up market share without a fight. Helen Palmer reports. (June 23, 2006)
Nurses in four cities have filed lawsuits naming two big hospital chains, saying their employers illegally shared wage information. They're demanding millions in back pay and other compensation. Janet Babin reports. (June 21, 2006)
Researchers report that a drug commonly used to treat heart disease might also help lessen the debilitating effects of stroke. But getting it to market as a stroke drug might be difficult. Helen Palmer reports. (June 20, 2006)
http://marketplace.publicradio.org/health.html
Gigi-Karen
